Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer

Published:2023-09-03 Issue:17 Volume:66 Page:12033-12058
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pulya Sravani¹,Himaja Ambati¹,Paul Milan²,Adhikari Nilanjan³^ORCID,Banerjee Suvankar³,Routholla Ganesh¹,Biswas Swati²^ORCID,Jha Tarun³^ORCID,Ghosh Balaram¹^ORCID

Affiliation:

1. Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad 500078, India

2. Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad 500078, India

3. Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, P.O. Box 17020, Kolkata, West Bengal 700032, India

Funder

Indian Council of Medical Research

Department of Science and Technology, Ministry of Science and Technology, India

Birla Institute of Technology and Science, Pilani

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00614

Reference123 articles.

1. Breast cancer